Abstract
Alzheimer's drug slows memory decline in phase 3 trial In September 2022, the pharmaceutical company Eisai announced that their drug, lecanemab, had shown small but clear benefits for people with early Alzheimer's, such as reductions in memory decline, in a rigorous, well-conducted phase 3 trial. Here Henry Scowcroft from Alzheimer's Research UK shows how the drug is one of several in development that work by removing a protein called amyloid from the brain, but it's the first that's been shown to slow down people's memory decline and thinking and improve day-to-day activities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
